CN101484159A - 通过使用加兰肽-3受体拮抗剂调节轴突外生长的方法 - Google Patents

通过使用加兰肽-3受体拮抗剂调节轴突外生长的方法 Download PDF

Info

Publication number
CN101484159A
CN101484159A CNA2007800241434A CN200780024143A CN101484159A CN 101484159 A CN101484159 A CN 101484159A CN A2007800241434 A CNA2007800241434 A CN A2007800241434A CN 200780024143 A CN200780024143 A CN 200780024143A CN 101484159 A CN101484159 A CN 101484159A
Authority
CN
China
Prior art keywords
aryl
branched
alkyl
straight
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800241434A
Other languages
English (en)
Chinese (zh)
Inventor
T·P·布莱克本
R·E·M·斯科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helicon Therapeutics Inc
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of CN101484159A publication Critical patent/CN101484159A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CNA2007800241434A 2006-06-26 2007-06-26 通过使用加兰肽-3受体拮抗剂调节轴突外生长的方法 Pending CN101484159A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81668206P 2006-06-26 2006-06-26
US60/816,682 2006-06-26

Publications (1)

Publication Number Publication Date
CN101484159A true CN101484159A (zh) 2009-07-15

Family

ID=38738789

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800241434A Pending CN101484159A (zh) 2006-06-26 2007-06-26 通过使用加兰肽-3受体拮抗剂调节轴突外生长的方法

Country Status (11)

Country Link
US (1) US20080039496A1 (enExample)
EP (1) EP2032135A2 (enExample)
JP (2) JP2009541493A (enExample)
CN (1) CN101484159A (enExample)
AU (1) AU2007265088B2 (enExample)
BR (1) BRPI0712938A2 (enExample)
CA (1) CA2655829A1 (enExample)
IL (1) IL195903A0 (enExample)
MX (1) MX2008016083A (enExample)
SG (1) SG172735A1 (enExample)
WO (1) WO2008002946A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642281B2 (en) * 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
BRPI0916228A2 (pt) * 2008-07-18 2015-11-03 Dart Neuroscience Llc métodos e sistemas para avaliação de agentes de memória
US20100028839A1 (en) * 2008-07-18 2010-02-04 Tully Timothy P Methods and systems for evaluating memory agents
EP2680842A4 (en) * 2011-03-02 2014-10-29 Bionomics Ltd METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
US8277842B1 (en) 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
PE20161476A1 (es) * 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
HUE050083T2 (hu) * 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081470B2 (en) * 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
EP2032135A2 (en) 2009-03-11
US20080039496A1 (en) 2008-02-14
JP2013227357A (ja) 2013-11-07
AU2007265088A1 (en) 2008-01-03
WO2008002946A3 (en) 2008-05-02
JP2009541493A (ja) 2009-11-26
AU2007265088B2 (en) 2013-05-23
IL195903A0 (en) 2009-09-01
MX2008016083A (es) 2009-03-20
WO2008002946A2 (en) 2008-01-03
BRPI0712938A2 (pt) 2013-03-26
SG172735A1 (en) 2011-07-28
CA2655829A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
AU2007265088B2 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
TWI873124B (zh) 用於治療腦機能障礙的n-取代吲哚及其他雜環
JP7612722B2 (ja) ＮＲ２ＢのＮ－アルキルアリール－５－オキシアリール－オクタヒドロ－シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
CA2620280C (en) Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
Zhang et al. Wnt/β-catenin signaling pathway contributes to isoflurane postconditioning against cerebral ischemia-reperfusion injury and is possibly related to the transforming growth factorβ1/Smad3 signaling pathway
JP6574769B2 (ja) 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
CN1639153A (zh) 吲哚基马来酰亚胺衍生物
JP5636091B2 (ja) 癌治療に用いるためのコンブレタスタチン類似体
US20120022083A1 (en) Small molecule modulators of cell adhesion
CN109563054B (zh) 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物
CN101406469B (zh) Gal3受体拮抗剂在治疗抑郁和/或焦虑中的应用及在这种方法中有用的化合物
WO2004093789A2 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
JPH08508743A (ja) Ｃｃｋおよび／またはガストリン拮抗作用を有する１，５−ベンゾジアゼピン誘導体
WO2004014376A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
JP5336194B2 (ja) 認知機能障害の処置に有用なインドロン化合物
WO2025164698A1 (ja) ハンチントン病治療剤及び治療用組成物
TW200410937A (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
US20200397901A1 (en) Photoresponsive smoothened ligand
NO342380B1 (no) Nye triazolderivater som ghrelinanalogligander av veksthormonutskillende reseptorer, anvendelse derav og farmasøytiske sammensetninger som inneholder slike
HK1127736B (en) Indolone compounds useful to treat cognitive impairment
TW200412968A (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090715